Product Description
| Product Name |
Retatrutide |
| CAS NO. |
2381089-83-2 |
| Other name |
LY3437943 GIPR/GLP-1R |
| Appearance |
White freeze dry Powder |
| Purity |
99.88%min. HPLC |
| Application |
Drug peptides |
| Shelf Life |
24Months |
| Storage |
Store at a temperature of 2-8 oC, protected from light |
Retatrutide represents an innovative breakthrough, meticulously crafted as a single molecule that ingeniously activates the receptors of three pivotal hormones within the human body - glucagon,
glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), each playing a crucial role in metabolic regulation. , and it is currently undergoing rigorous studies to uncover its promising potential in addressing obesity.
How is Retatrutide distinct from Semaglutideand Trizepatide?
Mechanism:
1. Semaglutide operates as a glucagon-like peptide-1 (GLP-1) hormone agonist, focusing primarily on enhancing secretion.
2. Tirezepatide functions as a dual hormone agonist (GLP-1 & GIP), effectively targeting both secretion and glucose regulation.
3. Retatrutide is unique, serving as a comprehensive triple hormone agonist (GLP-1, GIP, & Glucagon), offering a holistic approach to weight management.
Weight Loss in Clinical Trials:
1. Semaglutide has shown efficacy in achieving a 6-12% reduction of body weight over a period of 28 weeks, showcasing its potential in weight management.
2. Tirezepatide has delivered impressive results, achieving a significant 15-20% reduction in body weight over 72 weeks, marking its prowess as a weight loss solution.
3. Retatrutide stands out by demonstrating a remarkable 25% body weight reduction in just 48 weeks, underscoring its exceptional efficacy in clinical trials.
Audited Supplier 
){kind=link}